Press Release

PharmAla Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy

Toronto, ON – May 3, 2024 - PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has officially launched its Prescribers Portal for medical practitioners with prescribing power to learn more about MDMA, its effects, and the potential ability to access the molecule for their patients. The portal, which is currently live at, is available only to pre-approved medical professionals.

“With the upcoming review of MDMA for the treatment of PTSD by the US Food and Drug Administration, and with increasing insurance coverage in Canada for treatments based on psychedelic molecules, we believe it is important for medical practitioners to have access to high quality educational resources regarding MDMA, its effects, and its potential use for patients with Post-Traumatic Stress Disorder,” said Nicholas Kadysh, CEO, PharmAla Biotech. “As the research and regulatory environment regarding MDMA has moved quickly, most psychiatrists and medical practitioners are seeking information on clinical use and the regulatory pathways for MDMA access available in Canada. We hope our Prescribers Portal will meet this need.”

PharmAla’s Prescriber Portal will host tools and resources that assist medical practitioners in treating their patients. The Company also is working towards the creation of an accredited training and Continuing Education module for physicians in both Canada and Australia, which summarizes technical information pertaining to the clinical use of MDMA.

PharmAla will be hosting a webinar for medical practitioners on Wednesday, May 15th at 5 pm EST to demonstrate the platform, display its functionality, and answer questions. Only validated medical practitioners who have registered an account on the platform will have access to the webinar. To join, register at

About PharmAla

PharmAla Biotech Holdings Inc. (CSE: MDMA) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials, and to develop novel drugs in the same class. PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators. Our team of dedicated professionals includes regulatory experts, scientists, and biomanufacturing professionals. PharmAla has built what it believes to be North America’s first cGMP MDMA value chain, encompassing GMP manufacturing of Active Pharmaceutical Ingredient (API), and drug product formulation. PharmAla’s research and development unit has also begun preclinical research into two patented Novel Chemical Entities (NCEs) based on MDXX class molecules, with proof-of-concept research currently ongoing at the University of Arkansas Medical School.

Media Inquiries

Nicholas Kadysh, CEO